US · CYTK · BIOTECHNOLOGY
Cytokinetics, Incorporated (CYTK) intrinsic value and stock valuation
$50.78as of 2026-11-21 · Mkt cap 9.81B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Cytokinetics, Incorporated DCF and intrinsic value
InvestorsCraft values CYTK with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from CYTK’s statements →
Cytokinetics, Incorporated Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $88M | $18.5M | $7.53M | $94.6M | $70.4M |
| Operating income | -$-612.26M | -$-536.25M | -$-496.2M | -$-324.2M | -$-186.31M |
| Net income | -$-784.96M | -$-589.53M | -$-526.24M | -$-388.95M | -$-215.31M |
| EPSd | -$-6.54M | -$-5.26M | -$-5.45M | -$-4.33M | -$-2.8M |
| Operating cash flow | -$-510.01M | -$-395.89M | -$-414.33M | -$-299.52M | -$-142.52M |
| Capital expenditure | -$-24.81M | -$-3.91M | -$-1.42M | -$-11.34M | -$-48.87M |
| Free cash flow | -$-534.82M | -$-399.8M | -$-415.75M | -$-310.85M | -$-191.39M |
| Total assets | $1.42B | $1.4B | $824.3M | $1.01B | $841.3M |
| Total debt | $1.28B | $788.7M | $755.8M | $750.3M | $269.9M |
| Net debt | $1.16B | $693.8M | $642.8M | $684.7M | $157.3M |
| Total equity | -$-659.62M | -$-135.37M | -$-386.32M | -$-107.9M | $243.9M |
| Cash and short-term investments | $882.2M | $1.08B | $614.8M | $782.6M | $471.6M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $88M | $18.5M | $7.53M | $94.6M | $70.4M |
| Cost of revenue | $10.1M | $339.4M | $330.1M | $240.8M | $159.9M |
| Gross profit | $77.9M | -$-320.93M | -$-322.59M | -$-146.22M | -$-89.51M |
| Research and development expenses | $405.9M | $339.4M | $330.1M | $240.8M | $159.9M |
| Selling, general and administrative expenses | $284.3M | $215.3M | $173.6M | $178M | $96.8M |
| Other expenses | $0.00 | -$-339.41M | -$-330.12M | -$-240.81M | -$-159.94M |
| Operating expenses | $690.2M | $215.3M | $173.6M | $178M | $96.8M |
| Cost and expenses | $700.3M | $554.7M | $503.7M | $418.8M | $256.7M |
| Interest income | $48.4M | $51.5M | $27.6M | $11.3M | $330K |
| Interest expense | $103.9M | $86.5M | $57.7M | $51.2M | $29.3M |
| Depreciation and amortization | $9.69M | $9.53M | $11.9M | $8.4M | $9.64M |
| Ebitda | -$-775.27M | -$-493.48M | -$-456.68M | -$-329.4M | -$-176.34M |
| Operating income | -$-612.26M | -$-536.25M | -$-496.2M | -$-324.2M | -$-186.31M |
| Total other income/expenses, net | -$-172.7M | -$-53.28M | -$-30.04M | -$-64.75M | -$-29M |
| Income before tax | -$-784.96M | -$-589.53M | -$-526.24M | -$-388.95M | -$-215.31M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-784.96M | -$-589.53M | -$-526.24M | -$-388.95M | -$-215.31M |
| Weighted average shares outstanding | $120M | $112M | $96.5M | $89.8M | $76.9M |
| Weighted average diluted shares outstanding | $120.1M | $112M | $96.5M | $89.8M | $76.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $882.2M | $1.08B | $614.8M | $782.6M | $471.6M |
| Net receivables | $17.8M | $16.7M | $1.28M | $150K | $51.8M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $917M | $1.11B | $628.1M | $795.2M | $535.7M |
| Property, plant and equipment, net | $155.2M | $141M | $147.7M | $163.2M | $146.4M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $335.1M | $145.1M | $40.5M | $46.7M | $152.1M |
| Total non-current assets | $507.6M | $293.7M | $196.3M | $219.6M | $305.7M |
| Total assets | $1.42B | $1.4B | $824.3M | $1.01B | $841.3M |
| Accounts payable | $22.3M | $20.4M | $21.5M | $25.6M | $21.1M |
| Short-term debt | $60.3M | $30.5M | $28M | $13.8M | $14.9M |
| Deferred revenue | $1.61M | $52.4M | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $202.5M | $179.7M | $102.7M | $84.6M | $71.9M |
| Long-term debt | $1.22B | $758.2M | $727.8M | $736.5M | $255.1M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $87M |
| Total non-current liabilities | $1.88B | $1.36B | $1.11B | $1.04B | $525.6M |
| Capital lease obligations | $127.1M | $131.6M | $138.3M | $139.7M | $127.1M |
| Total liabilities | $2.08B | $1.54B | $1.21B | $1.12B | $597.5M |
| Common stock | $120K | $120K | $100K | $90K | $80K |
| Retained earnings | -$-3.49B | -$-2.7B | -$-2.11B | -$-1.59B | -$-1.21B |
| Accumulated other comprehensive income (loss) | $630K | $2.4M | -$-10K | -$-3.59M | -$-870K |
| Total equity | -$-659.62M | -$-135.37M | -$-386.32M | -$-107.9M | $243.9M |
| Total investments | $1.09B | $1.13B | $542.3M | $763.7M | $511M |
| Total debt | $1.28B | $788.7M | $755.8M | $750.3M | $269.9M |
| Net debt | $1.16B | $693.8M | $642.8M | $684.7M | $157.3M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-784.96M | -$-589.53M | -$-526.24M | -$-388.95M | -$-215.31M |
| Depreciation and amortization | $10.1M | $9.53M | $11.9M | $5.81M | $2.28M |
| Stock-based compensation | $112.3M | $97.8M | $72.1M | $47.9M | $26.8M |
| Change in working capital | -$-35.63M | $35.7M | $3.09M | -$-24.7M | $8.46M |
| Accounts receivable | -$-1.11M | -$-15.37M | -$-1.14M | $56.7M | -$-47.4M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $2.66M | -$-4.48M | -$-3.48M | $4.52M | $1.05M |
| Net cash provided by operating activities | -$-510.01M | -$-395.89M | -$-414.33M | -$-299.52M | -$-142.52M |
| Investments in property, plant and equipment | -$-24.81M | -$-3.91M | -$-1.42M | -$-11.34M | -$-48.87M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $250.8M | $98.9M |
| Net cash used for investing activities | $16.7M | -$-553.1M | $239.3M | -$-262.13M | -$-147.78M |
| Common stock issued | $36M | $706.8M | $164.2M | $17.5M | $312.1M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $524.5M | $930.6M | $221.3M | $516.2M | $320M |
| Net change in cash | $30.4M | -$-18.17M | $46.2M | -$-45.48M | $29.7M |
| Cash at end of period | $125.6M | $95.2M | $113.4M | $67.2M | $112.7M |
| Operating cash flow | -$-510.01M | -$-395.89M | -$-414.33M | -$-299.52M | -$-142.52M |
| Capital expenditure | -$-24.81M | -$-3.91M | -$-1.42M | -$-11.34M | -$-48.87M |
| Free cash flow | -$-534.82M | -$-399.8M | -$-415.75M | -$-310.85M | -$-191.39M |
Line items
Line items
Line items
About Cytokinetics, Incorporated
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
- CEO
- Robert I. Blum
- Employees
- 673
- Beta
- 0.38
Included in
Explore
Frequently asked questions
What is the intrinsic value of Cytokinetics, Incorporated (CYTK)?
Cytokinetics, Incorporated (CYTK) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is CYTK undervalued?
CYTK trades at a price of $50.78 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.